Roche Agrees To Acquire HCV Biotech Anadys For $230 Million

Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.